Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1737-1740

  Çoban, Şahin ^a   Ceydilek, Bilge ^a   Ekiz, Fuat ^a   Erden, Esra ^a   Soykan, Irfan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Hepatic failure; Levofloxacin

Indexed keywords

LEVOFLOXACIN;

ADULT; ARTICLE; ASCITES; CASE REPORT; CHRONIC HEPATITIS; CLINICAL FEATURE; COUGHING; DEATH; DETERIORATION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; FEVER; FLAPPING TREMOR; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATOMEGALY; HOSPITALIZATION; HUMAN; LIVER FAILURE; MALAISE; PERIPHERAL EDEMA; PLASMAPHERESIS; PRIORITY JOURNAL; RISK FACTOR; SORE THROAT; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; VIRUS CARRIER;

ANTI-BACTERIAL AGENTS; FATAL OUTCOME; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS B, CHRONIC; HUMANS; LIVER; MIDDLE AGED; OFLOXACIN; RESPIRATORY TRACT INFECTIONS;

EID: 25844486048     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G111     Document Type: Article

References (21)

1. Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000;22:798-817.
2. Gonzalez Carro P, Huidobro ML, Zabala AP, Vicente EM. Fatal subfulminant hepatic failure with ofloxacin (letter). Am J Gastroenterol 2000;95:1606.
3. Schwalm JD, Lee CH. Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. CMAJ 2003;168:847-8.
4. Karim A, Ahmed S, Rossoff LJ, Siddiqui RK, Steinberg HN. Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis 2001;33:2088-90.
5. Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A. Acute fatal hepatitis related to levofloxacin. J Hepatol 2001;35:308-9.
6. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med 1991;91(suppl 6A):153-61.
7. Jones SF, Smith RH. Quinolones may induce hepatitis. BMJ 1997;314: 869.
8. Fuchs S, Simon Z, Brezis M. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994;343:738-9.
9. Homann NE, Zambie MF. Gatifloxacin associated acute hepatitis. Pharmacotherapy 2001;21:1579-82.
10. Contreras MA, Luna R, Mulero J, Audreu JL. Severe ciprofloxacin-induced acute hepatitis. Eur J Clin Microbiol Infect Dis 2001;20:434-5.
11. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001;47(suppl 3):32-7.
12. Farrell GC. Liver disease caused by drugs, anesthetics, and toxins. In: Feldman M, Schaischmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's gastrointestinal and liver disease. 6th ed. Philadelphia: WB Saunders, 1998:1221-53.
13. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995;333:1118-27.
14. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals in the liver, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
15. Negro F, Male PJ, Perrin L, Giostra E, Hadengue A. Treatment of chronic hepatitis C with alpha interferon plus ofloxacin in patients not responding to alpha interferon alone. J Hepatol 1998;29:369-74.
16. Komatsu M, Ishii T, Ono T, Hoshino T, Kuramitsu T, Goto T, et al. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Can J Gastroenterol 1997;11:507-11.
17. Rastegar LA, Umrani G, Dehbashi N, Malec F. Evaluation of the therapeutic effect of pefloxacin in comparison with ampicillin and gentamicin in cirrhotic patients with spontaneous bacterial peritonitis. Hepatogastroenterology 1998;45:783-5.
18. Kojima H, Kaita KD, Hawkins K, Uhanova J, Minuk GY. Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother 2002;46:3280-2.
19. Nguyen MH, Garcia G. Does isoniazid cause more serious hepatotoxicity in hepatitis B virus carriers? Am J Gastroenterol 2002;97:1092-3.
20. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.